Bavarian Nordic

Bavarian Nordic A/S
Company typePublic
OTC Markets: BVNRY
ISINDK0015998017
IndustryBiotechnology
Founded1994; 30 years ago (1994)
Headquarters
Hellerup
,
Denmark[3]
Key people
ProductsImvanex, Imvamune, Jynneos, Rabipur/RabAvert, Encepur, Vivotif, Vaxchora, Mvabea
RevenueIncrease 7.062 billion kr. (2023)
Total assetsIncrease 14.373 billion kr. (2023)
Total equityIncrease 10.340 billion kr. (2023)
Number of employees
Increase 1.379 (2023)
Websitebavarian-nordic.com
Footnotes / references
[6]

Bavarian Nordic A/S is a fully integrated biotechnology company focused on the development, manufacturing and commercialization of vaccines. The company is headquartered in Hellerup, Denmark, with manufacturing facilities in Kvistgård, Denmark and Thörishaus [de] near Bern, Switzerland.[3] The company has research and development facilities in Martinsried, Germany and San Diego, California, as well as offices in Zug, Switzerland, and Morrisville, North Carolina. The company uses viral vectors and virus-like particles in its research and development.

  1. ^ "Archive.ph". Archived from the original on 13 March 2022. Retrieved 8 September 2023.{{cite web}}: CS1 maint: bot: original URL status unknown (link)
  2. ^ "OMX Copenhagen 25 (OMXC25CAP)" (PDF). Nasdaq OMX. Archived from the original (PDF) on 13 March 2022.
  3. ^ a b "Hellerup, Denmark". Bavarian Nordic. Archived from the original on 13 March 2022. Retrieved 6 December 2021.
  4. ^ "Board of Directors". BN. Retrieved 8 April 2024.
  5. ^ "Executive Management". BN. Archived from the original on 17 July 2020. Retrieved 8 April 2024.
  6. ^ "Annual Report 2023" (PDF). Bavarian Nordic. Archived from the original (PDF) on 2 April 2024. Retrieved 8 April 2024.